Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

107.71 -0.43 (-0.40%)
Streaming Delayed Price Updated: 9:30 AM EDT, Jun 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Why Axsome Therapeutics Stock Is Rising Today
The company provided its third-quarter update. 
Via The Motley Fool
2 Biotech Stocks Poised for Jaw-Dropping Growth
These two tiny drugmakers could make early shareholders wealthy. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Axsome Therapeutics Stock Rocketed Higher This Week
Optimism among investors is growing for the possible approval of the biotech's MDD drug. 
Via The Motley Fool
1 Beaten-Down Stock With 10X Potential
This biotech is down, but it isn't out just yet. 
Via The Motley Fool
45 Biggest Movers From Yesterday
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on... 
Via Benzinga
Why Axsome Therapeutics Stock Caught Fire in September
This beaten-down biotech regained some lost ground last month. 
Via The Motley Fool
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Axsome Therapeutics, Inc. 
Via SBWire
Exposures Product Safety
Why Wall Street Thinks This Biotech Stock Can Triple Your Money
The risks are huge, but so are the potential returns. 
Via The Motley Fool
Why Axsome Therapeutics Stock Cratered in August
An unexpected regulatory setback weighed heavily on the biotech's shares last month. 
Via The Motley Fool
3 Healthcare Stocks That Might Skyrocket When COVID Is Over
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over? 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Buy, Sell, or Hold Axsome Therapeutics Stock After Its FDA Approval Delay?
There are still plenty of unknowns related to Axsome's FDA filing. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
3 Biotech Stocks That Are Too Cheap to Ignore
You'll definitely want to check out these biotech bargains. 
Via The Motley Fool
Here's Why Axsome Therapeutics Stock Is Surging Today
The company still doesn't have much to say about the FDA and its experimental new anti-depression drug. 
Via The Motley Fool
Exposures Product Safety
10 Biggest Price Target Changes For Monday
Barclays raised Affirm Holdings, Inc. (NASDAQ:AFRM 
Via Benzinga
Which Biotech Stock Will Shock the Market in 2022?
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022? 
Via The Motley Fool
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/26/2021 -- Axsome Therapeutics, Inc is under investigation concerning possible securities laws violations in connection with certain financial statements. 
Via SBWire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC)... 
Via Benzinga
Why Axsome Therapeutics Stock Is Jumping Today
Investors are happy that the FDA didn't ask for more information to supplement Axsome's regulatory filing for AXS-05. 
Via The Motley Fool
Exposures Product Safety
Why Is Axsome Therapeutics (AXSM) Stock Shooting Higher On Monday?
Axsome Therapeutics Inc (NASDAQ: AXSM) stock is rising in premarket due to an update for its US marketing application seeking approval for AXS-05 for major... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 64.84% to $6.33 during Monday's pre-market session. The market value of their outstanding shares is at $144... 
Via Benzinga
The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More
Biotech stocks swayed back and forth before ending the week lower. With earnings news dying down and an empty initial public offerings calendar, it was broader market cues,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Could Biogen Acquire Axsome Therapeutics?
Here are three reasons why a buyout just might happen. 
Via The Motley Fool
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS